Cyclosporin for the treatment of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): a systematic review of observational studies and clinical trials focusing on single therapy, combination therapy, and comparative assessments

Amirhossein Nazerian,Alireza Jafarzadeh,Sadaf Salehi,Mobina Ghasemi,Azadeh Goodarzi
DOI: https://doi.org/10.1007/s10787-024-01590-0
2024-10-31
Inflammopharmacology
Abstract:Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, severe, and potentially life-threatening skin and mucous membrane disorders. They are characterized by widespread skin and mucosal detachment and necrosis, and are classified based on the percentage of total body surface area (TBSA) affected. Given the severe and often life-threatening nature of these conditions, the identification and implementation of effective treatments is crucial. Notably, cyclosporin has demonstrated efficacy in managing these challenging conditions.
immunology,toxicology
What problem does this paper attempt to address?